IL296246A - Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog - Google Patents

Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Info

Publication number
IL296246A
IL296246A IL296246A IL29624622A IL296246A IL 296246 A IL296246 A IL 296246A IL 296246 A IL296246 A IL 296246A IL 29624622 A IL29624622 A IL 29624622A IL 296246 A IL296246 A IL 296246A
Authority
IL
Israel
Prior art keywords
ionic surfactant
value less
hlb value
composition
equal
Prior art date
Application number
IL296246A
Other languages
English (en)
Hebrew (he)
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of IL296246A publication Critical patent/IL296246A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL296246A 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog IL296246A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462075866P 2014-11-05 2014-11-05
US201462075864P 2014-11-05 2014-11-05
PCT/US2015/059349 WO2016073798A1 (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog

Publications (1)

Publication Number Publication Date
IL296246A true IL296246A (en) 2022-11-01

Family

ID=54697646

Family Applications (7)

Application Number Title Priority Date Filing Date
IL296246A IL296246A (en) 2014-11-05 2015-11-05 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL295292A IL295292B2 (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL283699A IL283699B (en) 2014-11-05 2015-11-05 Methods and preparations related to artificial nanocarriers with rapamycin in a super-saturated steady state
IL251620A IL251620B (en) 2014-11-05 2017-04-06 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL251622A IL251622B (en) 2014-11-05 2017-04-06 Methods and compositions related to artificial nanocarriers with rapamycin in a supersaturated steady state
IL280518A IL280518B (en) 2014-11-05 2021-01-31 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL288609A IL288609B2 (en) 2014-11-05 2021-12-02 Methods and preparations related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog

Family Applications After (6)

Application Number Title Priority Date Filing Date
IL295292A IL295292B2 (en) 2014-11-05 2015-11-05 Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state
IL283699A IL283699B (en) 2014-11-05 2015-11-05 Methods and preparations related to artificial nanocarriers with rapamycin in a super-saturated steady state
IL251620A IL251620B (en) 2014-11-05 2017-04-06 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL251622A IL251622B (en) 2014-11-05 2017-04-06 Methods and compositions related to artificial nanocarriers with rapamycin in a supersaturated steady state
IL280518A IL280518B (en) 2014-11-05 2021-01-31 Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog
IL288609A IL288609B2 (en) 2014-11-05 2021-12-02 Methods and preparations related to the use of surfactants with low hlb in the production of artificial nanocarriers containing Reflog

Country Status (23)

Country Link
US (3) US20160128987A1 (enExample)
EP (6) EP4360633A3 (enExample)
JP (5) JP7218089B2 (enExample)
KR (2) KR102656139B1 (enExample)
CN (5) CN107072964A (enExample)
AU (4) AU2015342968B2 (enExample)
BR (3) BR122021025344B1 (enExample)
CA (2) CA2966852C (enExample)
CY (1) CY1124418T1 (enExample)
DK (4) DK3215133T3 (enExample)
EA (2) EA201790977A1 (enExample)
ES (4) ES2977259T3 (enExample)
FI (2) FI3834823T3 (enExample)
HR (1) HRP20210098T1 (enExample)
HU (4) HUE054894T2 (enExample)
IL (7) IL296246A (enExample)
LT (1) LT3215133T (enExample)
MX (4) MX383295B (enExample)
PL (1) PL3215133T3 (enExample)
PT (1) PT3215133T (enExample)
RS (1) RS61359B1 (enExample)
SI (1) SI3215133T1 (enExample)
WO (2) WO2016073798A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
CN107320734A (zh) 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
CN105307641A (zh) 2013-05-03 2016-02-03 西莱克塔生物科技公司 用于降低不期望体液免疫应答的给药组合
WO2015025538A1 (ja) * 2013-08-20 2015-02-26 サンノプコ株式会社 バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法
EA201790551A1 (ru) 2014-09-07 2017-07-31 Селекта Байосайенсиз, Инк. Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
WO2016132760A1 (ja) * 2015-02-17 2016-08-25 サンノプコ株式会社 バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法
US10973925B2 (en) 2015-04-28 2021-04-13 University Of Central Florida Research Foundation Inc. Methods and compositions for theranostic nanoparticles
RS65941B1 (sr) 2016-03-11 2024-10-31 Cartesian Therapeutics Inc Formulacije i doze pegilovane urikaze
KR102341902B1 (ko) * 2016-09-09 2021-12-21 카오카부시키가이샤 디카르복실산 결정 및 그 제조 방법
CN109922819A (zh) 2016-09-27 2019-06-21 西莱克塔生物科技公司 用于治疗癌症的重组免疫毒素
JP2020506890A (ja) 2017-01-07 2020-03-05 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
EP4599848A3 (en) 2017-03-11 2025-12-03 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2019075360A1 (en) 2017-10-13 2019-04-18 Selecta Biosciences, Inc. METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
KR20210119416A (ko) * 2019-01-24 2021-10-05 제너레이션 바이오 컴퍼니 폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
CA3141863A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
US20210154324A1 (en) * 2019-10-21 2021-05-27 Selecta Biosciences, Inc. Methods and compositions for treating liver diseases and disorders
IL292770A (en) 2019-11-08 2022-07-01 Selecta Biosciences Inc Formulations and dosages of polyethylene glycol-modified oricase
MX2022010568A (es) 2020-02-26 2022-11-30 Selecta Biosciences Inc Métodos y composiciones que usan nanoportadores sintéticos que comprenden inmunosupresor.
CA3174988A1 (en) * 2020-03-11 2021-09-16 Selecta Biosciences, Inc. Methods and compositions related to synthetic nanocarriers
KR20230002613A (ko) 2020-04-14 2023-01-05 셀렉타 바이오사이언시즈, 인크. 자가포식을 유도하기 위한 방법 및 조성물
MX2023005224A (es) 2020-11-04 2023-07-18 Selecta Biosciences Inc Composiciones para reducir las respuestas inmunes contra inmunoglobulina proteasas.
AU2022206197A1 (en) 2021-01-05 2023-07-13 Selecta Biosciences, Inc. Viral vector dosing protocols
KR102304785B1 (ko) 2021-03-26 2021-09-24 (주)진성티앤피 정밀광학기기의 부품 제조 방법
KR20230167405A (ko) 2021-04-09 2023-12-08 셀렉타 바이오사이언시즈, 인크. 면역 관용을 증진시키기 위해 고친화도 il-2 수용체 효능제와 조합된 면역억제제를 포함하는 합성 나노담체
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230140196A1 (en) 2021-10-12 2023-05-04 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
US20230263906A1 (en) 2022-01-10 2023-08-24 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
WO2023172628A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023196566A1 (en) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
JP2025526816A (ja) 2022-08-11 2025-08-15 カーティザン セラピューティクス，インコーポレーテッド 免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法
WO2024107889A1 (en) 2022-11-15 2024-05-23 Selecta Biosciences, Inc. Compositions and methods for treating primary biliary cholangitis
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
TWI877967B (zh) * 2023-12-28 2025-03-21 訊聯生物科技股份有限公司 包含小分子核糖核酸及奈米載體之組合物、包含其的醫藥組成物及其用途
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4806621A (en) 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US5736372A (en) 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5759830A (en) 1986-11-20 1998-06-02 Massachusetts Institute Of Technology Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5010167A (en) 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6187335B1 (en) 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
JP2002521423A (ja) 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
DE69930753D1 (de) * 1998-09-01 2006-05-18 Elan Corp Plc Dublin Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff-zusammensetzungen dazu
MXPA02008361A (es) 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
WO2003020797A1 (en) 2001-08-30 2003-03-13 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
CA2495913A1 (en) 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
CN1886100A (zh) * 2003-11-14 2006-12-27 阿尔萨公司 基于表面活性剂的凝胶作为可注射的持续药物递送载体
US20050260260A1 (en) 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
CN101291658B (zh) * 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
US8414910B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
AU2009268923B2 (en) * 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (en) * 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
EA201100765A1 (ru) * 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
KR101267813B1 (ko) * 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
JP6073788B2 (ja) * 2010-09-14 2017-02-01 ナノロジカ アクティエボラーグ 難水溶性医薬及び化粧品有効成分のための過飽和送達媒体
WO2012059936A1 (en) * 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
CN107320734A (zh) * 2011-04-29 2017-11-07 西莱克塔生物科技公司 从合成纳米载体中控制释放免疫抑制剂
CN102793674B (zh) * 2011-05-26 2014-11-26 澳门科技大学 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用
US20150272885A1 (en) 2011-10-14 2015-10-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
TWI439288B (zh) * 2012-10-05 2014-06-01 Univ China Medical 藥用載體及其製備方法與用途
CN102871966B (zh) * 2012-10-19 2013-11-20 东南大学 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法

Also Published As

Publication number Publication date
MX2021012273A (es) 2021-11-12
IL283699B (en) 2022-09-01
HUE053094T2 (hu) 2021-06-28
AU2021209202A1 (en) 2021-08-19
CA2966850A1 (en) 2016-05-12
AU2021209202B2 (en) 2023-11-30
KR20170081659A (ko) 2017-07-12
IL251620B (en) 2021-02-28
JP7827412B2 (ja) 2026-03-10
LT3215133T (lt) 2021-02-25
EA201790977A1 (ru) 2017-10-31
EP3834823A1 (en) 2021-06-16
EP3215133A1 (en) 2017-09-13
IL295292B1 (en) 2024-06-01
BR112017008499A2 (pt) 2017-12-26
JP2022173236A (ja) 2022-11-18
JP2023169893A (ja) 2023-11-30
CN115212186A (zh) 2022-10-21
EP3215192B1 (en) 2021-02-17
MX2017005903A (es) 2017-06-27
CN113244191A (zh) 2021-08-13
US20160128987A1 (en) 2016-05-12
IL251620A0 (en) 2017-06-29
WO2016073799A1 (en) 2016-05-12
HRP20210098T1 (hr) 2021-03-05
ES2977158T3 (es) 2024-08-20
AU2015342969A1 (en) 2017-04-27
RS61359B1 (sr) 2021-02-26
EP3215192A1 (en) 2017-09-13
EP4360633A2 (en) 2024-05-01
EP4356910A3 (en) 2024-05-22
KR102601922B1 (ko) 2023-11-15
IL280518A (en) 2021-03-01
IL295292B2 (en) 2024-10-01
EP4356910A2 (en) 2024-04-24
IL288609B (en) 2022-10-01
ES2865375T3 (es) 2021-10-15
JP6912377B2 (ja) 2021-08-04
IL251622B (en) 2021-06-30
IL283699A (en) 2021-07-29
FI3834823T3 (fi) 2024-04-02
DK3834823T3 (da) 2024-04-08
JP7218089B2 (ja) 2023-02-06
IL288609A (en) 2022-02-01
CA2966852C (en) 2024-01-02
ES2846809T3 (es) 2021-07-29
HUE066099T2 (hu) 2024-07-28
MX383295B (es) 2025-03-13
EP3215192A4 (en) 2018-05-02
SI3215133T1 (sl) 2021-07-30
KR102656139B1 (ko) 2024-04-11
WO2016073799A9 (en) 2016-12-08
CN107072964A (zh) 2017-08-18
DK3906918T3 (da) 2024-04-08
CA2966850C (en) 2024-03-26
MX2021006698A (es) 2021-07-07
MX386982B (es) 2025-03-19
DK3215192T3 (da) 2021-05-03
PT3215133T (pt) 2021-01-29
JP2021143180A (ja) 2021-09-24
BR122021025344B1 (pt) 2024-02-20
IL280518B (en) 2022-01-01
IL288609B2 (en) 2023-02-01
BR112017008720A2 (pt) 2017-12-19
AU2021209204A1 (en) 2021-08-19
WO2016073798A1 (en) 2016-05-12
CN107072965A (zh) 2017-08-18
AU2015342968A1 (en) 2017-04-27
US20250152561A1 (en) 2025-05-15
FI3906918T3 (fi) 2024-04-04
PL3215133T3 (pl) 2021-06-14
US20160128986A1 (en) 2016-05-12
DK3215133T3 (da) 2021-02-01
CN115212187A (zh) 2022-10-21
HUE054894T2 (hu) 2021-10-28
AU2015342969B2 (en) 2021-05-27
IL251622A0 (en) 2017-06-29
KR20170081660A (ko) 2017-07-12
CA2966852A1 (en) 2016-05-12
AU2015342968B2 (en) 2021-05-27
MX2017005904A (es) 2017-06-27
EP3906918A1 (en) 2021-11-10
JP2017537081A (ja) 2017-12-14
CY1124418T1 (el) 2022-07-22
EP4360633A3 (en) 2024-05-22
JP2017533243A (ja) 2017-11-09
BR112017008499B1 (pt) 2023-10-03
ES2977259T3 (es) 2024-08-21
EP3906918B1 (en) 2024-01-03
CN107072965B (zh) 2021-05-11
EP3834823B1 (en) 2024-01-03
IL295292A (en) 2022-10-01
EP3215133B1 (en) 2020-10-28
EA201790978A1 (ru) 2017-09-29
HUE067697T2 (hu) 2024-11-28

Similar Documents

Publication Publication Date Title
AU2021209202B2 (en) Methods and compositions related to the use of low HLB surfactants in the production of synthetic nanocarriers comprising a rapalog
US20210308058A1 (en) Methods and compositions related to synthetic nanocarriers